Cargando…

Pharmacogenomics‐Driven Prediction of Antidepressant Treatment Outcomes: A Machine‐Learning Approach With Multi‐trial Replication

We set out to determine whether machine learning–based algorithms that included functionally validated pharmacogenomic biomarkers joined with clinical measures could predict selective serotonin reuptake inhibitor (SSRI) remission/response in patients with major depressive disorder (MDD). We studied...

Descripción completa

Detalles Bibliográficos
Autores principales:	Athreya, Arjun P., Neavin, Drew, Carrillo‐Roa, Tania, Skime, Michelle, Biernacka, Joanna, Frye, Mark A., Rush, A. John, Wang, Liewei, Binder, Elisabeth B., Iyer, Ravishankar K., Weinshilboum, Richard M., Bobo, William V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6739122/ https://www.ncbi.nlm.nih.gov/pubmed/31012492 http://dx.doi.org/10.1002/cpt.1482

Ejemplares similares

Prediction of short-term antidepressant response using probabilistic graphical models with replication across multiple drugs and treatment settings
por: Athreya, Arjun P., et al.
Publicado: (2021)

Multi-omics driven predictions of response to acute phase combination antidepressant therapy: a machine learning approach with cross-trial replication
por: Joyce, Jeremiah B., et al.
Publicado: (2021)

Network science approach elucidates integrative genomic-metabolomic signature of antidepressant response and lifetime history of attempted suicide in adults with major depressive disorder
por: Grant, Caroline W., et al.
Publicado: (2022)

ERICH3: vesicular association and antidepressant treatment response
por: Liu, Duan, et al.
Publicado: (2020)

Beta-defensin 1, aryl hydrocarbon receptor and plasma kynurenine in major depressive disorder: metabolomics-informed genomics
por: Liu, Duan, et al.
Publicado: (2018)

Pharmacogenomics in Practice
por: Wang, Liewei, et al.
Publicado: (2019)

TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics
por: Gupta, M, et al.
Publicado: (2016)

Metformin Pharmacogenomics: Biomarkers to Mechanisms
por: Wang, Liewei, et al.
Publicado: (2014)

Multi-Omics Characterization of Early- and Adult-Onset Major Depressive Disorder
por: Grant, Caroline W., et al.
Publicado: (2022)

Pharmacogenomic Discovery to Function and Mechanism: Breast Cancer as a Case Study
por: Wang, Liewei, et al.
Publicado: (2017)

Dual Roles for the TSPYL Family in Mediating Serotonin Transport and the Metabolism of Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder
por: Qin, Sisi, et al.
Publicado: (2019)

Model-based unsupervised learning informs metformin-induced cell-migration inhibition through an AMPK-independent mechanism in breast cancer
por: Athreya, Arjun P., et al.
Publicado: (2017)

The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response
por: Biernacka, J M, et al.
Publicado: (2015)

The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response
por: Biernacka, J M, et al.
Publicado: (2016)

Evidence for machine learning guided early prediction of acute outcomes in the treatment of depressed children and adolescents with antidepressants
por: Athreya, Arjun P., et al.
Publicado: (2022)

Pharmacogenomics in depression and antidepressants
por: Bondy, Brigitta
Publicado: (2005)

54443 Pharmacogenomic Profiling of East and West African Populations
por: Jackson, Linsey, et al.
Publicado: (2021)

Gemcitabine and Arabinosylcytosin Pharmacogenomics: Genome-Wide Association and Drug Response Biomarkers
por: Li, Liang, et al.
Publicado: (2009)

Single Nucleotide Polymorphisms at a Distance from Aryl Hydrocarbon Receptor (AHR) Binding Sites Influence AHR Ligand–Dependent Gene Expression
por: Neavin, Drew R., et al.
Publicado: (2019)

Pharmacogenomics of antidepressant treatment effects
por: Licinio, Julio, et al.
Publicado: (2011)

Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients
por: Bhattacharyya, Sudeepa, et al.
Publicado: (2019)

Pharmacogenomic strategy for individualizing antidepressant therapy
por: Lin, Keh-Ming, et al.
Publicado: (2008)

The Role of the Aryl Hydrocarbon Receptor (AHR) in Immune and Inflammatory Diseases
por: Neavin, Drew R., et al.
Publicado: (2018)

Leveraging an Electronic Health Record-Linked Biorepository to Generate a Metformin Pharmacogenomics Hypothesis
por: Breitenstein, Matthew K., et al.
Publicado: (2015)

Breast cancer chemoprevention pharmacogenomics: Deep sequencing and functional genomics of the ZNF423 and CTSO genes
por: Liu, Duan, et al.
Publicado: (2017)

Genetic contributions to alcohol use disorder treatment outcomes: a genome-wide pharmacogenomics study
por: Biernacka, Joanna M., et al.
Publicado: (2021)

Pharmacogenomics: A focus on antidepressants and atypical antipsychotics
por: Lister, Jonathan F.
Publicado: (2016)

Pharmacogenomic testing and antidepressant response: problems and promises
por: Smith, Tawny L., et al.
Publicado: (2020)

TSPAN5 influences serotonin and kynurenine: pharmacogenomic mechanisms related to alcohol use disorder and acamprosate treatment response
por: Ho, Ming-Fen, et al.
Publicado: (2020)

Antidepressant-Associated Treatment Emergent Mania: A Meta-Analysis to Guide Risk Modeling Pharmacogenomic Targets of Potential Clinical Value
por: Nuñez, Nicolas A., et al.
Publicado: (2023)

An electronic health record driven algorithm to identify incident antidepressant medication users
por: Bobo, William V, et al.
Publicado: (2014)

Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments
por: Lin, Eugene, et al.
Publicado: (2021)

A model-based cost-effectiveness analysis of pharmacogenomic panel testing in cardiovascular disease management: preemptive, reactive, or none?
por: Zhu, Ye, et al.
Publicado: (2020)

Systematic review of the evidence on the cost-effectiveness of pharmacogenomics-guided treatment for cardiovascular diseases
por: Zhu, Ye, et al.
Publicado: (2019)

Polygenic risk scores for major depressive disorder and neuroticism as predictors of antidepressant response: Meta-analysis of three treatment cohorts
por: Ward, Joey, et al.
Publicado: (2018)

Pharmacists as facilitators of pharmacogenomic guidance for antidepressant drug selection and dosing
por: Bishop, Jeffrey R.
Publicado: (2021)

Pharmacogenomic biomarkers as source of evidence of the effectiveness and safety of antidepressant therapy
por: Correia, Catarina, et al.
Publicado: (2022)

Clinical predictors of response to methotrexate in patients with rheumatoid arthritis: a machine learning approach using clinical trial data
por: Duong, Stephanie Q., et al.
Publicado: (2022)

Impact of Pharmacogenomic Information on Values of Care and Quality of Life Associated with Codeine and Tramadol-Related Adverse Drug Events
por: Zhu, Ye, et al.
Publicado: (2021)

Current clinical evidence on pioglitazone pharmacogenomics
por: Kawaguchi-Suzuki, Marina, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_sch4e0bup25lg4hkseguekh5rk